tlr7 8 agonist r848 Search Results


tlr7/8 agonist-resiquimod (r 848)gel  (Syneos Health LLC)
90
Syneos Health LLC tlr7/8 agonist-resiquimod (r 848)gel
Use of <t> TLR7 </t> agonists as adjuvant in active clinical trials (* www.clinicaltrials.gov ).
Tlr7/8 Agonist Resiquimod (R 848)gel, supplied by Syneos Health LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr7+8+agonist+r848/tlr7+8+agonist+resiquimod++r+848+gel/pmc06295330-112-26-16
Average 90 stars, based on 1 article reviews
tlr7/8 agonist-resiquimod (r 848)gel - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Use of TLR7 agonists as adjuvant in active clinical trials (* www.clinicaltrials.gov ).

Journal: Cancer treatment reviews

Article Title: In vivo cancer vaccination: which dendritic cells to target and how?

doi: 10.1016/j.ctrv.2018.10.012

Figure Lengend Snippet: Use of TLR7 agonists as adjuvant in active clinical trials (* www.clinicaltrials.gov ).

Article Snippet: • Start date: 1st June 2018 • Completion date: July 2020 • Boston Biomedical, Inc • Syneos Health 4 NCT00960752 Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist Melanoma (71) • TLR7/8 agonist-Resiquimod (R 848)gel • Gp100 and MAGE-3 peptides • Phase II, randomized factorial assignment and open-label.

Techniques: Labeling

Use of TLR3 agonists as adjuvant in a selection of active clinical trials (* www.clinicaltrials.gov ).

Journal: Cancer treatment reviews

Article Title: In vivo cancer vaccination: which dendritic cells to target and how?

doi: 10.1016/j.ctrv.2018.10.012

Figure Lengend Snippet: Use of TLR3 agonists as adjuvant in a selection of active clinical trials (* www.clinicaltrials.gov ).

Article Snippet: • Start date: 1st June 2018 • Completion date: July 2020 • Boston Biomedical, Inc • Syneos Health 4 NCT00960752 Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist Melanoma (71) • TLR7/8 agonist-Resiquimod (R 848)gel • Gp100 and MAGE-3 peptides • Phase II, randomized factorial assignment and open-label.

Techniques: Selection, In Situ, Activity Assay, Immunofluorescence, Recombinant, Labeling